Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm

September 15, 2022 by nr9b@virginia.edu   |   Leave a Comment

Dr. Golam Mohi Congratulations to Dr. Golam Mohi on his paper published in Nature Communications titled: “Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm”

Author: Mohammed Ferdous-Ur Rahman1, Yue Yang1, Bao T. Le1, Avik Dutta 1, Julia Posyniak1, Patrick Faughnan1, Mohammad A. Sayem 1, Nadine S. Aguilera2 & Golam Mohi 1,3

Abstract: Chronic inflammation is frequently associated with myeloproliferative neo- plasms (MPN), but the role of inflammation in the pathogenesis of MPN remains unclear. Expression of the proinflammatory cytokine interleukin-1 (IL- 1) is elevated in patients with MPN as well as in Jak2V617F knock-in mice. Here, we show that genetic deletion of IL-1 receptor 1 (IL-1R1) normalizes peripheral blood counts, reduces splenomegaly and ameliorates bone marrow fibrosis in homozygous Jak2V617F mouse model of myelofibrosis. Deletion of IL-1R1 also significantly reduces Jak2V617F mutant hematopoietic stem/progenitor cells. Exogenous administration of IL-1β enhances myeloid cell expansion and accelerates the development of bone marrow fibrosis in heterozygous Jak2V617F mice. Furthermore, treatment with anti-IL-1R1 antibodies sig- nificantly reduces leukocytosis and splenomegaly, and ameliorates bone marrow fibrosis in homozygous Jak2V617F mice. Collectively, these results suggest that IL-1 signaling plays a pathogenic role in MPN disease progression, and targeting of IL-1R1 could be a useful strategy for the treatment of myelofibrosis.

Read Publication

 

Comments

Leave a Reply

Your email address will not be published.